Acquisition of INBRIJA (levodopa inhalation powder) and (F)AMPYRA (fampridine) expands specialty neurology portfolio Lays groundwork for Parkinson’s disease franchise and anchor in multiple sclerosis ...

Chance Pharmaceuticals Co. Ltd. acquired greater China rights to Inbrija (levodopa inhalation powder), used to manage Parkinson’s disease (PD), from Acorda Therapeutics Inc. in a deal worth as much as ...

Acorda Therapeutics said recently its levodopa inhalation powder for Parkinson disease (PD) has launched in Germany. The product, sold as Inbrija, is commercialized in Germany through an agreement ...

Levodopa inhalation powder is safe and effective in improving motor function during 'off' periods in patients with Parkinson's disease, suggest newly published results from the phase 3 SPAN-PD trial.